Tags

Type your tag names separated by a space and hit enter

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Ann Rheum Dis 2006; 65(1):35-9AR

Abstract

OBJECTIVE

To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis.

METHODS

The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively.

RESULTS

At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein.

CONCLUSIONS

Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.

Authors+Show Affiliations

Section of Allergy-Immunology-Rheumatology, Department of Medicine, Veterans General Hospital-Taipei, Taiwan. ctchou@vghtpe.gov.twNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15975966

Citation

Chen, H A., et al. "The Effect of Etanercept On Anti-cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Patients With Rheumatoid Arthritis." Annals of the Rheumatic Diseases, vol. 65, no. 1, 2006, pp. 35-9.
Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(1):35-9.
Chen, H. A., Lin, K. C., Chen, C. H., Liao, H. T., Wang, H. P., Chang, H. N., ... Chou, C. T. (2006). The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 65(1), pp. 35-9.
Chen HA, et al. The Effect of Etanercept On Anti-cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Patients With Rheumatoid Arthritis. Ann Rheum Dis. 2006;65(1):35-9. PubMed PMID: 15975966.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. AU - Chen,H A, AU - Lin,K C, AU - Chen,C H, AU - Liao,H T, AU - Wang,H P, AU - Chang,H N, AU - Tsai,C Y, AU - Chou,C T, Y1 - 2005/06/23/ PY - 2005/6/25/pubmed PY - 2006/1/20/medline PY - 2005/6/25/entrez SP - 35 EP - 9 JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. VL - 65 IS - 1 N2 - OBJECTIVE: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. METHODS: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively. RESULTS: At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein. CONCLUSIONS: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity. SN - 0003-4967 UR - https://www.unboundmedicine.com/medline/citation/15975966/The_effect_of_etanercept_on_anti_cyclic_citrullinated_peptide_antibodies_and_rheumatoid_factor_in_patients_with_rheumatoid_arthritis_ L2 - http://ard.bmj.com/cgi/pmidlookup?view=long&pmid=15975966 DB - PRIME DP - Unbound Medicine ER -